<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: In this study we investigated the effects of a novel compound, MS-153 ([R]-[-]-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1-nicotinoyl-2-pyrazoline), on elevated brain <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> concentrations and cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume induced by middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion in the rat </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The rat <z:chebi fb="70" ids="34342">MCA</z:chebi> was occluded by a <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> induced by a photochemical reaction between green light and the photosensitizer dye <z:chebi fb="0" ids="52261">rose bengal</z:chebi>, which causes endothelial injury followed by formation of a platelet- and fibrin-rich <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> at the site of photochemical reaction; this method is routinely used in our laboratory to produce <z:mp ids='MP_0006134'>arterial occlusion</z:mp> in experimental animals </plain></SENT>
<SENT sid="2" pm="."><plain>Extracellular <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> concentration at the ischemic border zone was determined by a microdialysis technique </plain></SENT>
<SENT sid="3" pm="."><plain>The size of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> was measured by a histochemical technique 24 hours after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>MS-153 was administered at various doses as a continuous infusion for 24 hours, beginning 0 to 2 hours after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At the ischemic border zone, the concentration of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> in the extracellular fluid increased by 40-fold after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>At 3.13 mg/kg per hour, MS-153 reduced <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> concentration (P &lt; .05) and also the size of <z:e sem="disease" ids="C1262005" disease_type="Disease or Syndrome" abbrv="">ischemic cerebral infarction</z:e> (P &lt; .05) </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, the <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> uptake inhibitor DL-threo-beta-hydroxyaspartate reversed the effect of MS-153 on <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> concentration </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The reduction in the size of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> by MS-153 may be attributable to the inhibition of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> release or an increase in cellular <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> uptake </plain></SENT>
</text></document>